The development of novel C-2, C-8, and N-9 trisubstituted purines as inhibitors of TNF-α production

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 16, 2006, Pages 4360-4365

  Sabat, Mark ^a   VanRens, John C ^a   Clark, Michael P ^a   Brugel, Todd A ^a   Maier, Jennifer ^a   Bookland, Roger G ^a   Laufersweiler, Matthew J ^a   Laughlin, Steven K ^a   Golebiowski, Adam ^a   De, Biswanath ^a   Hsieh, Lily C ^a   Walter, Richard L ^b   Mekel, Marlene J ^b   Janusz, Michael J ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^b Miami Valley Innovation Center   (United States)

Author keywords

MAP kinase; Mutated p38; p38; Purines; THP 1; THP 1 cell; TNF

Indexed keywords

LIPOPOLYSACCHARIDE; PURINE DERIVATIVE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MONOCYTE; PROTEIN SYNTHESIS INHIBITION; STRUCTURE ACTIVITY RELATION; X RAY ANALYSIS;

CELL LINE; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; LIPOPOLYSACCHARIDES; MODELS, CHEMICAL; MODELS, MOLECULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PURINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745713217     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.05.050     Document Type: Article

References (40)

1. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., McNulty D., Blumenthal M.J., Heys J.R., and Landvatter S.W. Nature 372 (1994) 739
2. Han J., Lee J.-D., Bibbs L., and Ulevitch R.J. Science 265 (1994) 808
3. For recent reviews, see:. Adams J.L., Badger A.M., Kumar S., and Lee J.C. In: King F.D., and Oxford A.W. (Eds). Progress in Medicinal Chemistry Vol. 38 (2001), Elsevier, Amsterdam 1-60
4. Chen Z., Gibson T.B., Robinson F., Silvestro L., Pearson G., Xu B.-e., Wright A., Vanderbilt C., and Cobb M.H. Chem. Rev. 101 (2001) 2449
5. Enslen H., and Davis R. Biol. Cell 93 (2001) 5
6. Kumar S., Boehm J., and Lee J.C. Nat. Rev. Drug Disc. 2 (2003) 717
7. Johnson G.L., and Lapadat R. Science 298 (2002) 1911 For representations of the MAPK signaling cascade, see Refs. 2a,d,e
8. Pargellis C., and Regan J. Curr. Opin. Invest. Drugs 4 (2003) 566
9. Smolen J.S., and Steiner G. Nat. Rev. Drug Disc. 2 (2003) 473
10. Baugh J.A., and Bucala R. Curr. Opin. Drug Disc. Devel. 4 (2001) 635
11. Brennan F.M., and Feldman M. Curr. Opin. Immunol. 8 (1996) 872
12. Camussi G., and Lupia E. Drugs 55 (1998) 613
13. Newton R.C., and Decicco C.P. J. Med. Chem. 42 (1999) 2295
14. Foster M.L., Halley F., and Souness J.E. Drug News Perspect. 13 (2000) 488
15. Palladino M.A., Bahjat F.R., Theodorakis E.A., and Moldawer L.L. Nat. Rev. Drug Disc. 2 (2003) 736
16. Boehm J.C., and Adams J.L. Expert Opin. Ther. Patents 10 (2000) 25
17. Wilson K.P., McCaffrey P.G., Hsiao K., Pazhanisamy S., Galullo V., Bemis G.W., Fitzgibbon M.J., Caron P.R., Murcko M.A., and Su M.S.S. Chem. Biol. 4 (1997) 423
18. Cirillo P.F., Pargellis C., and Regan J. Curr. Top. Med. Chem. 2 (2002) 1021
19. Chakravarty S., and Dugar S. Annu. Rep. Med. Chem. 37 (2002) 177
20. Wang Z., Canagarajah B.J., Boehm J.C., Kassisa S., Cobb M.H., Young P.R., Abdel-Meguid S., Adams J.L., and Goldsmith E.J. Structure 6 (1998) 1117
21. Ferraccioli G.F. Curr. Opin. Anti-Inflamm. Immunodulatory Invest. Drugs 2 (2000) 74
22. Fitzgerald C.E., Patel S.B., Becker J.W., Cameron P.M., Zaller D., Pikounis V.B., O'Keefe S.J., and Scapin G. Nat. Struct. Biol. 10 (2003) 764
23. Huwe A., Mazitschek R., and Giannis A. Angew. Chem., Int. Ed. 42 (2003) 2122
24. Wang Y., Metcalf C.A., Shakespeare W.C., Sundaramoorthi R., Keenan T.P., Bohacek R.S., van Schravendijk M.R., Violette S.M., Narula S.S., Dalgarno D.C., Haraldson C., Keats J., Liou S., Mani U., Pradeepan S., Ram M., Adams S., Weigele M., and Sawyer T.K. Bioorg. Med. Chem. Lett. 13 (2003) 3067
25. Dymock B., Barril X., Beswick M., Collier A., Davies N., Drysdale M., Fink A., Fromont C., Hubbard R.E., Massey A., Surgenor A., and Wright L. Bioorg. Med. Chem. Lett. 14 (2004) 325
26. Otyepka M., Krystof V., Havlicek L., Siglerova V., Strnad M., and Koca J. J. Med. Chem. 43 (2000) 2506
27. Whittaker N., and Jones T.S.G. J. Chem. Soc. Abstracts (1951) 1565
28. 1H NMR) see:. Taylor E.C., and Thompson M.J. J. Org. Chem. 26 (1961) 5224 The unwanted regioisomer was removed after the second desired displacement (intermediates 2 and 4).
29. Seth P.P., Robinson D.E., Jefferson E.A., and Swayze E.E. Tetrahedron Lett. 43 (2002) 7303
30. Huang K.T., and Sun C.M. Bioorg. Med. Chem. Lett. 12 (2002) 1001
31. Guerret P., Ancher J.F., and Langlois M. J. Heterocycl. Chem. 20 (1983) 1525
32. 15 (Promega Co., Madison, WI).
33. Mohler K.M., Sleath P.R., Fitzner J.N., Cerretti D.P., Alderson M., Kerwar S.S., Torrance D.S., Otten-Evans C., Greenstreet T., Weerawarna K., Kronhelm S.R., Petersen M., Gerhart M., Kozlosky C.J., March C.J., and Black R.A. Nature 370 (1994) 218
34. Barltrop J.A., Owen T.C., Cory A.H., and Cory J.G. Bioorg. Med. Chem. Lett. 1 (1991) 611
35. 19 X-ray data were collected at beamline 17-BM in the facilities of the Industrial Macromolecular Crystallography Association Collaborative Access Team (IMCA-CAT) at the Advanced Photon Source. These facilities are supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Illinois Institute of Technology (IIT), executed through IIT's Center for Synchrotron Radiation Research and Instrumentation. Use of the Advanced Photon Source was supported by the US Department of Energy, Basic Energy Sciences, Office of Science, under Contract No. W-31-109-Eng-38.
36. Wang Z., Harkins P.C., Ulevitch R.J., Han J., Cobb M.H., and Goldsmith E.J. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2327
37. Han J., Lee J.D., Bibbs L., and Ulevitch R.J. Science 265 (1994) 808
38. Pav S., Whit D.M., Rogers S., Crane K.M., Cywin C.L., Davidson W., Hopkins J., Brown M.L., Pargellis C.A., and Tong L. Protein Sci. 6 (1997) 242
39. Measured as percent loss at 4 h in rat hepatocytes.
40. In vitro metabolism assay procedure: In vitro metabolic stability of analogs in plated rat hepatocytes (Sprague-Dawley) obtained from Cedra Corporation. Metabolic activity was determined in triplicate using a total volume of 0.2 mL containing 0.25 μM NCE incubated in rat hepatocyte and matrigel blank microtiter plates. The plates were maintained at 37 °C throughout the study. Samples were removed from wells at 0, 2, and 4 h, and NCE samples were analyzed by HP-LC/MS/MS with reverse-phase chromatography. To improve analytical efficiency, compounds were grouped together (post-incubation) into a multi-compound assay. Samples from like time-points containing the different compounds were combined and an internal standard (1.1 ng/mL stock) was added. Results for each compound were expressed as the ratio of the compound response area over the internal standard response area. Percent loss was calculated by dividing the 2 and 4 h ratios by the 0 h ratio.